6. パーキンソン病 Parkinson disease Clinical trials / Disease details
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05266417 (ClinicalTrials.gov) | February 7, 2022 | 23/2/2022 | Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD) | Parkinson Disease | Drug: INS-GSH;Drug: Matched Placebos | Gateway Institute for Brain Research | NULL | Recruiting | 30 Years | 85 Years | All | 56 | Phase 2 | United States |
| 2 | NCT02424708 (ClinicalTrials.gov) | April 2015 | 15/4/2015 | Phase IIb Study of Intranasal Glutathione in Parkinson's Disease | Phase IIb Study of Intranasal Glutathione in Parkinson's Disease | Parkinson's Disease | Drug: Reduced Glutathione 100mg;Drug: Reduced Glutathione 200mg;Drug: Placebo | Bastyr University | Michael J. Fox Foundation for Parkinson's Research | Completed | 21 Years | N/A | Both | 45 | Phase 2 | United States |
| 3 | NCT02324426 (ClinicalTrials.gov) | December 2014 | 4/12/2014 | CNS Uptake of Intranasal Glutathione | Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease | Parkinson's Disease | Drug: Reduced Glutathione | University of Washington | Michael J. Fox Foundation for Parkinson's Research | Completed | 18 Years | N/A | Both | 15 | Phase 1 | United States |
| 4 | NCT01398748 (ClinicalTrials.gov) | July 2012 | 19/7/2011 | Intranasal Glutathione in Parkinson's Disease | A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease | Parkinson's Disease (PD) | Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal Delivery | Bastyr University | National Center for Complementary and Integrative Health (NCCIH) | Completed | 21 Years | 100 Years | All | 34 | Phase 1 | United States |
| 5 | NCT01177319 (ClinicalTrials.gov) | September 2003 | 5/8/2010 | Glutathione (GSH) In The Treatment of Parkinson's Disease | Glutathione (GSH) In The Treatment of Parkinson's Disease | Parkinson's Disease | Drug: Glutathione | University of South Florida | Wellness Health & Pharmaceuticals, Inc. | Completed | 18 Years | N/A | Both | 20 | Phase 2 | United States |